Glioblastoma AGILE Trial
A Major Step Toward Precision Medicine for Malignant Brain Tumors
Precision Medicine for Malignant Brain Tumors
HEALTHY PARTICIPANTS: No
University Hospitals-Seidman Cancer Center is part of the world’s largest Phase II/III responsive adaptive randomization brain cancer clinical trial. GBM AGILE is designed to evaluate multiple therapies in newly diagnosed and recurrent glioblastoma patients. It is a major step towards precision medicine for these malignant tumors and to identify the most effective therapies for each patient.
Purpose of Study
The study is an adaptive randomization trial in which multiple drugs and combinations of drugs are screened simultaneously and over time. Unlike most clinical trials, this study can be modified based on the results and information obtained from participants and therapies can be redefined in each individual patient as the trial goes on.
Who Can Participate?
Patients 18 years or older who have been newly diagnosed with glioblastoma (GBM) or recurrent GBM may be eligible to participate in the study.
Learn More About This Research Study
For more information, please contact Christopher Murphy, RN, the study coordinator at 216-983-3021 or contact us using the online form below.